Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

J. Arab

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.

DESCRIPTION Steatotic liver disease (SLD) is the leading cause of chronic liver disease and liver-related mortality in the United States. The 2023 multisociety consensus nomenclature was intended to develop a more evidence-based framework regarding the differing forms of SLD, including metabolic dysfunction-associated...

J. Arab, H. Malhi, G. S. Winder et al. · 0 citations
Open access Sep 2026

Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD, and the FIB-4 demonstrated lower accuracy for predicting advanced fibrosis in lean vs overweight/obese MASLD.

L. de Avila, K. Al-Naamani, M. Papatheodoridi et al. · 1 citation
Review Oct 2026

Alcohol-associated liver disease.

Alcohol-associated liver disease (ALD) is the leading cause of liver-related mortality in Western countries. The assessment of histological severity in ALD now relies predominantly on non-invasive methods, particularly elastography and blood-based tests, commercially available or laboratory-developed. These non-invasiv...

Brian P. Lee, Haripriya Maddur, J. Arab et al. · 0 citations
Review Open access Oct 2026

Review Article: Fibrosis-4 Index in Steatotic Liver Disease-Past, Present and Future.

In the precision therapy era, FIB-4 remains a scalable front-door test but should not serve as a stand-alone selector for drug eligibility; confirmatory staging is required to identify F2-F3 disease and exclude cirrhosis.

K. Soni, V. Jahagirdar, Omar Albhaisi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.